Healthcare
China's HighLight to exit US-based biotech player Bonti
Chinese healthcare-focused GP HighLight Capital is set to exit its position in US-based biotechnology company Bonti after Allergan agreed to acquire the business for $195 million, plus additional payments if certain development targets are met.
KKR to buy Life Healthcare stake in India hospital JV
KKR has agreed to pay INR4.3 billion ($59.6 million) to South African hospital chain Life Healthcare Group for its stake in Max Healthcare, a hospital operator that it owns through a joint venture with Max India.
PE-backed WuXi AppTec targets Hong Kong listing
Wuxi AppTec, a contract pharmaceutical R&D services provider backed by several private equity investors, has filed for a Hong Kong listing less than four months after listing in Shanghai. The size and pricing of the IPO have yet to be decided, but the...
Hong Kong Asia Medical receives $150m from General Atlantic
Hong Kong Asia Medical, a privately-owned Chinese cardiology hospital operator, has received a $150 million investment from General Atlantic amid escalating interest from global investors toward China’s biotech and healthcare industry.
OPIC commits $150m to Quadria healthcare fund
The Overseas Private Investment Corporation (OPIC), a development finance arm of the US government, has committed $150 million to Quadria Capital II, the latest fund of healthcare-focused PE firm Quadria Capital.
Deal focus: GTJA targets China online pharmacy boom
Healthcare specialist GTJA Investment Group leads a $130 million Series B for Jianke in the expectation that the company will consolidate its leadership position in China's online pharmacy market
China healthcare big data platform gets $30m Series B
Weimai, a Chinese healthcare-focused big data platform that operates on a city-by-city basis, has received $30 million in Series B funding led by Cenova Ventures, Source Code Capital, Vision Plus Capital, and Matrix Partners China.
China Renaissance set for wealth management push
China Renaissance Holdings is planning an aggressive push into wealth management services, targeting high net worth individuals in China’s new economy, with proceeds from its upcoming Hong Kong IPO.
PE-backed Chinese online pharmacy completes $100m US IPO
Chinese online pharmacy operator 111 Inc – best known for its 1 Drugsstore platform – traded down slightly on its NASDAQ debut after raising $100.5 million in a scaled back IPO.
Carlyle invests in Chinese pharma industry supplier
The Carlyle Group has paid an undisclosed sum for a significant minority stake in Ambio, a US-based pharmaceuticals company with substantial operations in China.
China's Jianke raises $130m Series B
Chinese online pharmacy operator Jianke has closed a $130 million Series B funding round led by healthcare-focused GTJA Investment Group.
India's Netmeds gets $45m Series C round
Indian online drug marketplace operator Netmeds has received a $45 million Series C funding round with participation from Russian venture capital investor Sistema Asia Fund.
Qiming, Hillhouse back China's Jacobio Pharma
Chinese drug maker Jacobio has secured a $55 million Series C funding round led by Qiming Venture Partners and Hillhouse Capital, with participation from Prudence Investment Management.
Adamantem to buy Australia's Zenitas Healthcare
Adamantem Capital has agreed to buy Australia-based Zenitas Healthcare in a deal worth approximately A$122 million ($88 million), including debt. It is working with Liverpool Partners, an investment and advisory firm with extensive experience in healthcare.
VinaCapital launches VC arm, agrees three deals
Vietnam’s VinaCapital has launched a $100 million VC unit and confirmed its first two domestic investments. Separately, the private equity firm has committed $25 million to a local hospital operator.
GIC leads $85m Series B for China's Harbour BioMed
Harbour BioMed, a China-based biopharmaceutical company focused on treatments for cancer and autoimmune disorders, has raised an $85 million Series B round led by Singapore’s GIC Private.
GPs support $590m investment in take-private target China Biologic
China Biologic Products, a US-listed biopharmaceuticals player that was subject to two take-private offers, said it was set to raise $590 million by issuing new shares to investors including Centurium Capital, CITIC Capital, and Hillhouse Capital.
China’s GL commits $12.5m to UK-listed healthtech platform
GL Capital, a healthcare-focused GP based in China, has invested GBP9.75 million ($12.5 million) in UK-listed health technology platform Oxford BioDynamics (OBD) as part of a larger partnership aimed at expansion in China.
CDH-backed Mabpharm files for Hong Kong IPO
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, has filed for an IPO in Hong Kong, the latest in a growing number of proposed listings under new rules that allow biotech companies with no revenue or profits to go public.
Sequoia India closes sixth fund at $695m
Sequoia Capital India has closed its sixth fund at $695 million, surpassing a target range of $625-675 million.
China’s Ascentage Pharma files for HK IPO
Ascentage Pharma, a Chinese biopharmaceutical company with several private equity backers, has filed for an IPO in Hong Kong.
China Biologic Products receives competing take-private offer
US-listed China Biologic Products has received a buyout offer worth $3.9 billion from a consortium including former CEO David Gao and CDH Investments. It follows a $3.6 billion bid last month by CITIC Capital.
Matrix raises $300m for third India fund
Matrix Partners has raised $300 million for its third India-focused venture capital fund, which will back companies in sectors including consumer and enterprise technology and financial technology.
Chinese online drugstore operator targets US listing
Chinese online pharmacy operator 111 Inc, which counts ClearVue Partners, Verlinvest and BioVeda Capital among its investors, has filed for an IPO in the US.
